Combination of bifunctional alkylating agent and arsenic trioxide synergistically suppresses the growth of drug-resistant tumor cells.
Drug resistance is a crucial factor in the failure of cancer chemotherapy. In this study, we explored the effect of combining alkylating agents and arsenic trioxide (ATO) on the suppression of tumor cells with inherited or acquired resistance to therapeutic agents. Our results showed that combining ATO and a synthetic derivative of 3a-aza-cyclopenta[a]indenes (BO-1012), a bifunctional alkylating agent causing DNA interstrand cross-links, was more effective in killing human cancer cell lines (H460, H1299, and PC3) than combining ATO and melphalan or thiotepa. We further demonstrated that the combination treatment of H460 cells with BO-1012 and ATO resulted in severe G(2)/M arrest and apoptosis. In a xenograft mouse model, the combination treatment with BO-1012 and ATO synergistically reduced tumor volumes in nude mice inoculated with H460 cells. Similarly, the combination of BO-1012 and ATO effectively reduced the growth of cisplatin-resistant NTUB1/P human bladder carcinoma cells. Furthermore, the repair of BO-1012-induced DNA interstrand cross-links was significantly inhibited by ATO, and consequently, gammaH2AX was remarkably increased and formed nuclear foci in H460 cells treated with this drug combination. In addition, Rad51 was activated by translocating and forming foci in nuclei on treatment with BO-1012, whereas its activation was significantly suppressed by ATO. We further revealed that ATO might mediate through the suppression of AKT activity to inactivate Rad51. Taken together, the present study reveals that a combination of bifunctional alkylating agents and ATO may be a rational strategy for treating cancers with inherited or acquired drug resistance.
Lee
Pei-Chih
PC
Institute of Pharmacology, School of Medicine, National Yang-Ming University, Taipei, Taiwan, Republic of China.
Kakadiya
Rajesh
R
Su
Tsann-Long
TL
Lee
Te-Chang
TC
D000818:Animals; D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology*; D017209:Apoptosis; D000077237:Arsenic Trioxide; D001152:Arsenicals / Q000008:administration & dosage*; D015153:Blotting, Western; D002219:Carbamates / Q000008:administration & dosage*; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects*; D002469:Cell Separation; D019008:Drug Resistance, Neoplasm / Q000187:drug effects; D004357:Drug Synergism; D005434:Flow Cytometry; D005455:Fluorescent Antibody Technique; D006575:Heterocyclic Compounds, 3-Ring / Q000008:administration & dosage*; D006801:Humans; D007150:Immunohistochemistry; D020287:In Situ Nick-End Labeling; D008297:Male; D051379:Mice; D008819:Mice, Nude; D009374:Neoplasms, Experimental / Q000188:drug therapy*; D010087:Oxides / Q000008:administration & dosage*; D015398:Signal Transduction / Q000187:drug effects*; D023041:Xenograft Model Antitumor Assays
D018906:Antineoplastic Agents, Alkylating; D001152:Arsenicals; C000591165:BO-1012; D002219:Carbamates; D006575:Heterocyclic Compounds, 3-Ring; D010087:Oxides; D000077237:Arsenic Trioxide
Mol Cancer Res. 2009 Aug;7(8):1378-89
19671683
Curr Med Chem. 2009;16(19):2355-65
19601785
Biochem Pharmacol. 1992 Mar 3;43(5):1101-7
1554383
Nat Rev Cancer. 2008 Mar;8(3):193-204
18256616
Blood. 2001 Jul 15;98(2):266-71
11435292
Cancer. 2009 Jul 1;115(13):2964-70
19402172
Nat Cell Biol. 2005 Feb;7(2):195-201
15665856
Nature. 2001 Aug 2;412(6846):557-61
11484058
Arch Toxicol. 1991;65(8):640-5
1747062
Curr Med Res Opin. 2009 Jan;25(1):149-60
19210148
Int J Cancer. 1994 Jan 2;56(1):134-9
8262670
Mol Cells. 2008 Aug 31;26(2):158-64
18596414
Int J Radiat Oncol Biol Phys. 2006 Jun 1;65(2):493-8
16563655
Br J Haematol. 2007 Aug;138(4):467-78
17587338
J Formos Med Assoc. 1992 Jun;91(6):608-13
1358347
World J Gastroenterol. 2001 Oct;7(5):702-5
11819858
Annu Rev Med. 2002;53:437-52
11818484
J Exp Med. 2004 Jun 21;199(12):1671-7
15197225
Cancer Res. 2008 Nov 15;68(22):9404-12
19010915
Chem Biol Interact. 2007 Jun 30;168(2):159-68
17512921
Biochemistry. 2005 Mar 22;44(11):4148-56
15766242
Lancet Oncol. 2001 Aug;2(8):483-90
11905724
Pharmacol Ther. 1997 Oct-Dec;76(1-3):73-87
9535170
Bone Marrow Transplant. 2005 Dec;36(11):939-45
16184181
Toxicology. 2003 Nov 15;193(1-2):161-9
14599775
Eur J Pharmacol. 2009 Dec 25;625(1-3):143-50
19836377
Ann Surg. 1931 Jan;93(1):190-9
17866462
Clin Lymphoma Myeloma. 2006 Nov;7(3):192-8
17229334
Biol Blood Marrow Transplant. 2008 Dec;14(12):1401-7
19041063
Cancer Res. 2001 Jul 15;61(14):5432-40
11454688
Bioorg Med Chem. 2009 Aug 1;17(15):5614-26
19576785
Zhonghua Zhong Liu Za Zhi. 2001 Nov;23(6):487-9
11859717
Mol Cancer Res. 2008 Sep;6(9):1431-9
18819931
Toxicol Appl Pharmacol. 2006 Aug 1;214(3):309-17
16494910
Urology. 2002 Aug;60(2):346-50
12137851
Cancer Res. 2006 Feb 15;66(4):2098-106
16489010
Cancer Chemother Pharmacol. 2000;46(5):423-6
11127948
Toxicol Appl Pharmacol. 2008 May 1;228(3):385-94
18252256
Cancer Sci. 2003 Nov;94(11):1010-4
14611680
Cancer Res. 2004 Dec 15;64(24):8960-7
15604259
Cancer. 2005 Oct 15;104(8):1687-92
16130126
Nat Rev Cancer. 2005 Jan;5(1):65-72
15630416
Cell Signal. 2002 Dec;14(12):969-75
12359302
Invest New Drugs. 2002 Aug;20(3):327-30
12201495
Expert Opin Investig Drugs. 2007 Sep;16(9):1467-87
17714032
Biol Blood Marrow Transplant. 2009 May;15(5):523-36
19361744
Mutat Res. 1985 Jan-Feb;148(1-2):83-9
3969080
J Clin Oncol. 2001 Sep 15;19(18):3852-60
11559723
Cancer Res. 2010 Jan 15;70(2):440-6
20068163
Environ Health Perspect. 2006 Aug;114(8):1193-8
16882524
Onkologie. 2008 May;31(5):271-81
18497518
Pharmacol Rev. 2006 Sep;58(3):621-81
16968952
FEBS Lett. 2002 May 22;519(1-3):195-200
12023044
Cancer Sci. 2008 Feb;99(2):187-94
17953711
DNA Repair (Amst). 2007 Jan 4;6(1):61-70
17011244
Curr Med Chem. 2009;16(5):522-37
19199919
Toxicol Appl Pharmacol. 2008 Oct 1;232(1):41-50
18619636
Cancer Chemother Pharmacol. 2007 Feb;59(2):183-95
16724239